Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. (Q34621157)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20596778%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

0 references

1 reference

title

Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20596778%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

0 references

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20596778%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Patrick D Meek

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20596778%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Samuel D Evang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20596778%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Dianne Roux-Lirange

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20596778%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Darren M Triller

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20596778%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Bora Gumustop

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20596778%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

2 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20596778%20AND%20SRC:MED&resulttype=core&format=json

Digestive Diseases and Sciences

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20596778%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20596778%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20596778%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

7-18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20596778%20AND%20SRC:MED&resulttype=core&format=json

Bias in meta-analysis detected by a simple, graphical test

6 February 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10620-010-1313-3

Better reporting of harms in randomized trials: an extension of the CONSORT statement

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10620-010-1313-3

Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial

21 January 2018

1 reference

12 December 2020

Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder

1 reference

12 December 2020

Assessment of cognitive function of the elderly population: effects of darifenacin

1 reference

12 December 2020

Multicenter phase III trial studying trospium chloride in patients with overactive bladder

1 reference

12 December 2020

Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo

1 reference

12 December 2020

The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study

1 reference

12 December 2020

Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults

1 reference

12 December 2020

Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial

1 reference

12 December 2020

Which anticholinergic drug for overactive bladder symptoms in adults

1 reference

12 December 2020

Clinical efficacy and tolerability of extended‐release tolterodine and immediate‐release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo‐controlled trial

1 reference

12 December 2020

Prevalence and burden of overactive bladder in the United States

1 reference

12 December 2020

Controlling the risk of spurious findings from meta-regression.

1 reference

12 December 2020

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

1 reference

12 December 2020

Operating characteristics of a rank correlation test for publication bias

1 reference

12 December 2020

Anticholinergic drugs versus other medications for overactive bladder syndrome in adults

1 reference

12 December 2020

Pharmacologic options for the overactive bladder

1 reference

12 December 2020

Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.

1 reference

12 December 2020

Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study

1 reference

12 December 2020

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

1 reference

12 December 2020

Meta-analysis in clinical trials

1 reference

12 December 2020

Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder

1 reference

12 December 2020

Bowel care in the elderly

1 reference

12 December 2020

Methods for assessing drug-related anticholinergic activity

1 reference

12 December 2020

An investigation of dose titration with darifenacin, an M3-selective receptor antagonist

1 reference

12 December 2020

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial

1 reference

12 December 2020

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

1 reference

12 December 2020

Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial

1 reference

12 December 2020

Use of health care resources and cost of care for adults with constipation

1 reference

12 December 2020

Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program

1 reference

12 December 2020

Ambulatory care for constipation in the United States, 1993-2004

1 reference

12 December 2020

Measuring inconsistency in meta-analyses

1 reference

12 December 2020

Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.

1 reference

12 December 2020

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial

1 reference

12 December 2020

Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis

1 reference

12 December 2020

Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan

1 reference

12 December 2020

Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder

1 reference

12 December 2020

Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia

1 reference

12 December 2020

Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence

1 reference

12 December 2020

Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder

1 reference

12 December 2020

Predictors of discontinuing overactive bladder medications

1 reference

12 December 2020

Tolterodine: a safe and effective treatment for older patients with overactive bladder

1 reference

12 December 2020

Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder

1 reference

12 December 2020

Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial

1 reference

12 December 2020

Advancements in pharmacologic management of the overactive bladder

1 reference

12 December 2020

Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients

1 reference

12 December 2020

Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence

1 reference

12 December 2020

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

12 December 2020

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

12 December 2020

Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes

1 reference

12 December 2020

Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome

1 reference

12 December 2020

Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial

1 reference

12 December 2020

Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder

1 reference

12 December 2020

Anticholinergic effects of medication in elderly patients.

1 reference

12 December 2020

Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial

1 reference

12 December 2020

Cumulative incidence of chronic constipation: a population-based study 1988-2003.

1 reference

12 December 2020

Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study

1 reference

12 December 2020

Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study

1 reference

12 December 2020

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder

1 reference

12 December 2020

Chronic gastrointestinal symptoms in the elderly

1 reference

12 December 2020